09:48 AM EST - StageZero Life Sciences, Ltd. : Announced that people throughout the Greater Toronto Area can now access the company's multi-cancer blood test ARISTOTLE®. Built on StageZero's proprietary mRNA technology, ARISTOTLE® is a next-generation test which simultaneously screens for multiple cancers from a single sample of blood. StageZero Life Sciences, Ltd.
shares T.SZLS are trading up $0.01 at $0.27.
